BLEOCINCopy

• DRUGBANK - Bleomycin
• indication:

  For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.

• pharmacology:

• mechanism:

  Although the exact mechanism of action of bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis. DNA cleavage by bleomycin depends on oxygen and metal ions, at least in vitro. It is believed that bleomycin chelates metal ions (primarily iron) producing a pseudoenzyme that reacts with oxygen to produce superoxide and hydroxide free radicals that cleave DNA.

• toxicity:

  Excessive exposure may cause fever, chills, nausea, vomiting, mental, confusion, and wheezing. Bleomycin may cause irritation to eyes, skin and respiratory tract. It may also cause a darkening or thickening of the skin. It may cause an allergic reaction.

• absorprion:

  Systemic absorption is approximately 45%.

• halflife:

  115 minutes

• roouteelimination:

  It was reported that patients with moderately severe renal failure excreted less than 20% of the dose in the urine.

• volumedistribution:

• clearance: